Search - tctmd.com

Displaying 361 - 380 of 457

Sort: Relevancy | Date

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Michael O'Riordan

March 15, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

Shelley Wood

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Daily News

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Yael L. Maxwell

March 08, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Features

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

L.A. McKeown

February 26, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

L.A. McKeown

January 22, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Caitlin E. Cox

January 08, 2018

News Daily News

AAFP Says It Cannot Endorse New Hypertension Guideline

Todd Neale

December 18, 2017

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

Advertisement

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Less Aggressive HbA1c Targets Recommended by American College of Physicians

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

AAFP Says It Cannot Endorse New Hypertension Guideline

Genetic Study Hints at Role of Lipids in AAA Risk

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content